Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis – still of value for our patients?

Bibliography

• Van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985;8426:425-9
   Google Scholar
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013 65:1-11
   Google Scholar
• Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ. Small vessel vasculitis. N Engl J Med 1997;337:1512-23
   PubMed Web of Science ®Google Scholar
• Luqmani R. Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol 2013;9:127-32
   Google Scholar
• Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-10
   PubMed Web of Science ®Google Scholar
• Millet A, Pederzoli-Ribeil M, Guillevin L, et al. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis 2013;72:1273-9
   PubMed Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013;65:270-81
   PubMed Web of Science ®Google Scholar
• Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94
   PubMed Web of Science ®Google Scholar
• Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002;61(1):80-9
   PubMed Web of Science ®Google Scholar
• Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides. The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-62
   PubMed Web of Science ®Google Scholar
• Fauci AS, Wolff SM. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973;52:535-61
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85
   PubMed Web of Science ®Google Scholar
• Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener´s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98
   PubMed Web of Science ®Google Scholar
• Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-17
   PubMed Web of Science ®Google Scholar
• Mahr A, Katsahian S, Varet H, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2013;72:1003-10
   PubMed Web of Science ®Google Scholar
• Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997;72:737-47
   PubMedGoogle Scholar
• De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9
   PubMed Web of Science ®Google Scholar
• Jones R, Harper L, Ballarin J, et al. A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. Presse Médicale 2013;42:678-9; abstract
   Web of Science ®Google Scholar
• Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8
   PubMed Web of Science ®Google Scholar
• Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013;14:73
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32
   PubMed Web of Science ®Google Scholar
• Rahmattulla C, de Lind van Wijngaarden RA, Berden AE, et al. Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the european vasculitis society clinical trials. Rheumatology (Oxford) 2015;54:899-907
   Google Scholar
• Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. dutch co-trimoxazole wegener study group. N Engl J Med 1996;335:16-20
   PubMed Web of Science ®Google Scholar
• Walsh M, Faurschou M, Berden A, et al. Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2014;9:1571-6
   PubMed Web of Science ®Google Scholar
• Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012;71:955-60
   PubMed Web of Science ®Google Scholar
• Faurschou M, Westman K, Rasmussen N, et al. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3472-7
   PubMedGoogle Scholar
• Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement – a prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010;5:445-53
   PubMedGoogle Scholar
• Pusey CD, Rees AJ, Evans DJ, et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757-63
   PubMed Web of Science ®Google Scholar
• Walsh M, Casian A, Flossmann O, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013;84:397-402
   PubMed Web of Science ®Google Scholar
• Pepper RJ, Chanouzas D, TarzI R, et al. Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013;8:219-24
   PubMed Web of Science ®Google Scholar
• Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis – a clinical randomized controlled trial. Nephrol Dial Transplant 2011;26:206-13
   PubMed Web of Science ®Google Scholar
• Gregersen JW, Kristensen T, Krag SR, et al. Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin Exp Rheumatol 2012;30(Suppl 70):S39-47
   Google Scholar
• Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011;57:566-74
   PubMed Web of Science ®Google Scholar
• Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2014. [Epub ahead of print]
   Google Scholar
• Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-27
   PubMed Web of Science ®Google Scholar
• Jones RB, Furuta S, Cohen Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015. [Epub ahead of print]
   Google Scholar
• Latimer NR, Carroll C, Wong R, et al. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: A NICE single technology appraisal. Pharmacoeconomics 2014;32:1171-83
   Google Scholar
• Mansfield N, Hamour S, Habib AM, et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011;26:3280-6
   Google Scholar
• De Joode AA, Sanders JS, Rutgers A, Stegeman CA. Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for long? Nephrol Dial Transplant 2015. [Epub ahead of print]
   Google Scholar
• Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621-31
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody–associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008;58:2908-18
   PubMed Web of Science ®Google Scholar
• Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8
   PubMed Web of Science ®Google Scholar
• Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011;63:257-66
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381-8
   PubMed Web of Science ®Google Scholar
• Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005;352:351-61
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80
   PubMed Web of Science ®Google Scholar
• Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener´s granulomatosis. Rheumatology (Oxford) 2007;46:1087-91
   PubMed Web of Science ®Google Scholar
• Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760-9
   PubMed Web of Science ®Google Scholar
• Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who receive repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 2014. [ Epub ahead of print]
   Google Scholar
• Belimumab in Remission of VASculitis (BREVAS). Available from: https://clinicaltrials.gov/ct2/show/NCT01663623 [Last accessed 3 March 2015]
   Google Scholar
• Rituximab Vasculitis Maintenance Study (RITAZAREM). Available from: https://clinicaltrials.gov/ct2/show/NCT01697267 [Last accessed 3 March 2015]
   Google Scholar
• Tervaert JW, Huitema MG, Hené RJ, et al. Prevention of relapses in Wegener´s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11
   PubMed Web of Science ®Google Scholar
• Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener´s granulomatosis. Arthritis Rheum1993;36:365-71
   PubMed Web of Science ®Google Scholar
• Girard T, Mahr A, Noel LH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener´s granulomatosis? A prospective study. Rheumatology (Oxford) 2001;40:147-51
   PubMed Web of Science ®Google Scholar
• Nowack R, Grab I, Flores-Suarez LF, et al. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2001;16:1631-7
   PubMed Web of Science ®Google Scholar
• Rasmussen N, Salmela A, Ekstrand A, et al. Changes in proteinases 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener´s) may reflect treatment rather than disease activity. Clin Exp Rheumatol 2013;31(Suppl 75):S38-44
   Google Scholar
• Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 2014
   PubMedGoogle Scholar
• Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 2014;53:2306-9
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis. Arthritis Rheum 2012;64:3770-8
   PubMed Web of Science ®Google Scholar
• Charles P, Néel A, Tieulié N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford) 2014;53:532-9
   PubMed Web of Science ®Google Scholar
• Tesar V, Hruskova Z. Limitations of standard immunosuppressive treatment in ANCA-associated vasculitis and lupus nephritis. Nephron Clin Pract 2014;128:205-15
   PubMedGoogle Scholar
• Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-84
   PubMed Web of Science ®Google Scholar
• Rutgers A, Kallenberg CG. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr Opin Rheumatol 2012;24:245-51
   PubMed Web of Science ®Google Scholar
• KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012(Suppl):139
   Google Scholar
• Guillevin L. Treatment of severe and/or refractory ANCA-associated vasculitis. Curr Rheumatol Rep 2014;16:430
   Google Scholar
• Karras A, Jayne D. New biologics for glomerular disease on the horizon. Nephron Clin Pract 2014;128:283-91
   Google Scholar
• Bomback AS, Appel GB, Radhakrishnan J, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int 2011;79:757-64
   Google Scholar
• Sacri AS, Chambraud T, Ranchin B, et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vaculitis: a French nationwide study. Nephrol Dial Transplant 2015. [Epub ahead of print]
   Google Scholar
• De Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013;8:1709-17
   PubMed Web of Science ®Google Scholar
• Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66:1535-40
   PubMed Web of Science ®Google Scholar
• Srivastava A, Rao GK, Segal PE, et al. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol 2013;32:1317-22
   PubMed Web of Science ®Google Scholar
• Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener´s granulomatosis): comparison of efficacy in granulomatous versus vasculitis manifestations. Ann Rheum Dis 2012;71:327-33
   PubMed Web of Science ®Google Scholar
• Martinez Del Pero M, Chaudhry A, Jones RB, et al. B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study. Clin Otolaryngol 2009;34:328-35
   PubMed Web of Science ®Google Scholar
• Joshi L, Tanna A, McAdoo SP, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology 2015;122(6):1262-8
   PubMed Web of Science ®Google Scholar
• Alberici F, Jayne DR. Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Nephrol Dial Transplant 2014;29:1151-9
   PubMed Web of Science ®Google Scholar
• Wong L, Harper L, Little MA. Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis. Nephrol Dial Transplant 2015;30(suppl 1):i164-70
   Google Scholar
• Gregersen JW, Chaudhry A, Jayne DR. Rituximab for ANCA-associated vasculitis in the setting of severe infection. Scand J Rheumatol 2013;42:207-10
   PubMed Web of Science ®Google Scholar
• de Groot K, Pusey C. End-Stage Renal Disease and Vasculitis. In: Hoffman GS, Weyand CM, Langford CA, Goronzy JJ, Editors Inflammatory diseases of blood vessels. 2nd Edition. Oxford, Wiley-Blackwell; UK: 2012. p. 534-43
   Google Scholar
• Hruskova Z, Geetha D, Tesar V. Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 2014. [Epub ahead of print]
   Google Scholar
• Weidemann S, Andrassy K, Ritz E. ANCA in hemodialysis patients. Nephrol Dial Transplant 1993;8:839-45
   PubMed Web of Science ®Google Scholar
• Romeu M, Couchoud C, Delarozière JC, et al. Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011. QJM 2014;107:545-55
   PubMed Web of Science ®Google Scholar
• Tang W, Bose B, McDonald SP, et al. The outcomes of patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. Clin J Am Soc Nephrol 2013;8:773-80
   PubMed Web of Science ®Google Scholar
• Marco H, Mirapeix E, Arcos E, et al. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant 2013;27:338-47
   PubMed Web of Science ®Google Scholar
• Lee T, Gasim A, Derebail VK, et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 2014;9:905-13
   PubMed Web of Science ®Google Scholar
• de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 2007;18:2189-97
   Google Scholar
• Weidanz F, Day CJ, Hewins P, et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 2007;50:36-46
   PubMed Web of Science ®Google Scholar
• Lionaki S, Hogan SL, Jennette CE, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 2009;76:644-51
   PubMed Web of Science ®Google Scholar
• Little MA, Hassan B, Jacques S, et al. Renal transplantation in systemic vasculitis: when is it safe? Nephrol Dial Transplant 2009;24:3219-25
   PubMed Web of Science ®Google Scholar
• Floege J, Regele H, Gesualdo L; ERA-EDTA Immunonephrology Working Group. The ERA-EDTA database on recurrent glomerulonephritis following renal transplantation. Nephrol Dial Transplant 2014;29:15-21
   Google Scholar
• Murakami C, Manoharan P, Carter-Monroe N, Geetha D. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant. Transpl Int 2013;26:1225-31
   PubMed Web of Science ®Google Scholar
• Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74:177-84
   PubMed Web of Science ®Google Scholar
• Little M, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 2015. [Epub ahead of print]
   Google Scholar
• Lai QY, Ma TT, Li ZY, et al. Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients. J Rheumatol 2014;41:1849-55
   PubMed Web of Science ®Google Scholar
• Cohen Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 2013;27:33-44
   Google Scholar
• Faurschou M, Mellemkjaer L, Sorensen IJ, et al. Increased morbidity from ischemic heart disease in patients with Wegener´s granulomatosis. Arthritis Rheum 2009;60:1187-92
   PubMed Web of Science ®Google Scholar
• Petermann Smits DR, Wilde B, et al. Metabolic syndrome in ANCA-associated vasculitis. Rheumatology (Oxford) 2013;52:197-203
   PubMed Web of Science ®Google Scholar
• Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trial. Ann Rheum Dis 2011;70:1415-21
   PubMed Web of Science ®Google Scholar
• Mahr A, Heijl C, Le Guenno G, et al. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol 2013;27:45-56
   PubMedGoogle Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener´s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5
   PubMed Web of Science ®Google Scholar
• Westman K, Flossmann O, Gregorini G. The long-term outcomes of systemic vasculitis. Nephrol Dial Transplant 2015. [Epub ahead of print]
   Google Scholar
• Hilhorst M, Wilde B, van Paassen P, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 2013;28:373-9
   PubMed Web of Science ®Google Scholar
• Charles P, Bienvenu B, Bonnotte B, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013;42:1317-30
   PubMed Web of Science ®Google Scholar